Dhillon Niku, Macleod Shona
Department of Ophthalmology, National Treatment Centre Highland, Inverness, UK.
J Vitreoretin Dis. 2025 Aug 10:24741264251358623. doi: 10.1177/24741264251358623.
To evaluate the incidence of intraocular inflammation (IOI) after intravitreal (IVT) faricimab injection. A retrospective observational study was performed of all patients who received IVT faricimab injections at NHS Highland between January 2023 and June 2024 and subsequently developed IOI. IOI was seen in 11 eyes of 6 patients after faricimab injection. All aqueous and vitreous cultures were negative. Among patients who received bilateral faricimab injections, the incidence of IOI was 8.5% (5/59). Four eyes experienced a vision loss of 11.5 ± 8.6 Early Treatment Diabetic Retinopathy Study letters. Cases were characterized by a delayed onset of subacute symptoms after injection, keratic precipitates, and elevated intraocular pressure. Although the overall incidence of faricimab-related IOI is low, our findings highlight the need for increased vigilance in patients receiving bilateral faricimab injections.
评估玻璃体内注射法西单抗后眼内炎症（IOI）的发生率。对2023年1月至2024年6月在英国国家医疗服务体系高地接受玻璃体内注射法西单抗且随后发生IOI的所有患者进行了一项回顾性观察研究。法西单抗注射后，在6例患者的11只眼中观察到了IOI。所有房水和玻璃体培养均为阴性。在接受双侧法西单抗注射的患者中，IOI的发生率为8.5%（5/59）。4只眼的视力下降了11.5±8.6个早期糖尿病性视网膜病变研究字母。病例的特征为注射后亚急性症状延迟出现、角膜后沉着物和眼压升高。尽管与法西单抗相关的IOI总体发生率较低，但我们的研究结果强调了对接受双侧法西单抗注射的患者提高警惕的必要性。
